T cell and immune cell engagement is gaining traction, but what makes it different from other therapies? Patrick Baeuerle, Ph.D., chief scientific advisor at Cullinan Therapeutics, and Jeffrey Miller, M.D., deputy director of Masonic Cancer Center, join The Chain to discuss the advantages, similarities, and differences of T cell and immune cell engagers, and how they compare to other modalities such as CAR T cells. Hosted by Laszlo Radvanyi, Ph.D., their conversation covers engineering recognition of multiple targets, prospects for peptide MHC engagers and NK cells engagers, and the application of these modalities to oncology and beyond.
Links from this episode:
University of Toronto, Department of Immunology
University of Toronto
Cullinan Therapeutics
Masonic Cancer Center
